Search





Search





Markets
/
Stocks
/
nasdaq-vrdn
/

Viridian Therapeutics Inc

VRDN

Add to Watchlist

18.480USD

+0.110+0.60%

Close 07/01, 16:00（ET）Quotes delayed by 15 min

2.04BMarket Cap

LossP/E TTM

Viridian Therapeutics Inc

18.480

+0.110+0.60%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey 图表

Intraday

30m

Today

+0.60%

5 Days

+6.70%

1 Month

+8.96%

6 Months

-40.62%

Year to Date

-40.62%

1 Year

+27.71%

Key Figures

18.740Open

19.340High

3.27MVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

3.19%Turnover Ratio

18.370Prev. Close

18.425Low

48.08MTurnover

LossP/E Static

3.76P/B

0.00%Div Yield TTM

-49.74%ROA

34.29052wk High

0.82Volume Ratio

-269.95MNet Profit

102.46MShares

-3.9978EPS TTM

0.88Beta

-78.43%ROE

13.18052wk Low

4.98%Amplitude

100.00%Gross Margin

2.04BMarket Cap

4.84Reward/Risk

3.25%Risk Rate

TradingKey Stock Score of Viridian Therapeutics Inc

Currency: USD Updated: 2026-07-01

Key Insights

Viridian Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 40 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.33.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Viridian Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

40 / 387

Overall Ranking

125 / 4564

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Viridian Therapeutics Inc Highlights

StrengthsRisks

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22463.38% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 70.85M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 70.85M.

Undervalued

The company’s latest PE is -4.62, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 116.15M shares, increasing 5.38% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 187.72K shares of this stock.